Pulmonary Hypertension

Chatterjee, Kanu; Marco, Teresa De; Alpert, Joseph S.

doi:10.1001/archinte.162.17.1925

Cited by 46 publications

(2 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Baseline TRFV was higher than would be expected in these dogs if the increase was solely because of passive increases in LA pressure. However, an increase in pulmonary vascular resistance may accompany long‐standing increases in LA pressure, producing a mixed hemodynamic response 5,6,41 …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of Pimobendan and N‐Terminal Probrain Natriuretic Peptide in the Treatment of Pulmonary Hypertension Secondary to Degenerative Mitral Valve Disease in Dogs

Atkinson

Fine

Thombs

et al. 2009

Veterinary Internal Medicne

View full text Add to dashboard Cite

Background: Pimobendan is a positive inotrope and vasodilator that may be useful in the treatment of pulmonary hypertension (PHT) secondary to degenerative mitral valve disease.Hypothesis: Pimobendan decreases the severity of PHT measured echocardiographically and improves quality-of-life scores. Changes in N-terminal probrain natriuretic peptide (NT-proBNP) concentrations will reflect improvement in severity of PHT.Animals: Ten client-owned dogs with peak tricuspid regurgitant flow velocity (TRFV) !3.5 m/s. Methods: Prospective short-term, double-blinded, crossover design, with a long-term, open-label component. Short term, dogs were randomly allocated to receive either placebo or pimobendan (0.18-0.3 mg/kg PO q12 h) for 14 days. After a 1-week washout, they received the alternative treatment for 14 days, followed by pimobendan open-label for 8 weeks.Results: Short-term comparison: peak TRFV decreased in all dogs on pimobendan compared with placebo from a median of 4.40 (range, 3.2-5.6) to 3.75 (range, 2.4-4.8) m/s (P o .0001). NT-proBNP concentration decreased after treatment with pimobendan from a median of 2,143 (range, 450-3,981) to 1,329 (range, 123-2,411) pmol/L (P 5 .0009). All dogs improved their quality-of-life score (P 5 .006). In the long-term comparisons, peak TRFV decreased in all dogs from a median of 4.28 (range, 3.5-5.7) to 3.52 (range, 2.4-5.0) m/s (P o .0001). No significant changes in NT-proBNP or quality-of-life scores were detected.Conclusions and Clinical Importance: Pimobendan lowered severity of measurable PHT, improved quality-of-life scores, and decreased NT-proBNP concentrations short-term. Long term, only the reduction in TRFV was maintained.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Pulmonary hypertension (PHT) is defined as an increase in pulmonary arterial pressure (PAP). Systolic PAP >30 mmHg or mean PAP >20 mmHg confirms the diagnosis of PHT 1–9 . Three mechanisms may contribute to increased PAP: increased left atrial (LA) pressure, increased pulmonary blood flow, and increased pulmonary vascular resistance.…”

mentioning

confidence: 96%

Evaluation of Pimobendan and N‐Terminal Probrain Natriuretic Peptide in the Treatment of Pulmonary Hypertension Secondary to Degenerative Mitral Valve Disease in Dogs

Atkinson

Fine

Thombs

et al. 2009

Veterinary Internal Medicne

View full text Add to dashboard Cite

show abstract

Computed tomography and magnetic resonance imaging of pulmonary hypertension: Pulmonary vessels and right ventricle

Ley¹,

Grünig²,

Kiely³

et al. 2010

Magnetic Resonance Imaging

View full text Add to dashboard Cite

Pulmonary hypertension (PH) is very heterogeneous and the classification identifies five major groups including many associated disease processes. The treatment of PH depends on the underlying cause and accurate classification is paramount. A comprehensive assessment to identify the cause and severity of PH is therefore needed. Furthermore, follow‐up assessments are required to monitor changes in disease status and response to therapy. Traditionally, the diagnostic imaging work‐up of PH comprised mainly echocardiography, invasive right heart catheterization, and ventilation/perfusion scintigraphy. Due to technical advances, multidetector row computed tomography (CT) and magnetic resonance imaging (MRI) have become important and complementary investigations in the evaluation of patients with suspected PH. Both modalities are reviewed and recommendations for clinical use are given. J. Magn. Reson. Imaging 2010;32:1313–1324. © 2010 Wiley‐Liss, Inc.

show abstract

Malignant infantile osteopetrosis & primary pulmonary hypertension: A new combination?

Kasow

Bonfim

Asch

et al. 2003

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Malignant infantile osteopetrosis (MIOP), a rare genetic disorder of the osteoclast, is fatal without hematopoietic stem cell transplantation. Primary pulmonary hypertension (PPH), a rare progressive disorder of the pulmonary circulation, is predominantly fatal in the absence of successful therapy. A clinical association between these two disorders has not been recognized and a pathophysiologic link between osteoclast function and pulmonary vascular pressure as a rationale for such an association is not readily apparent. Here, we report five infants with MIOP, without cardiac abnormalities, who were found to have PPH after undergoing stem cell transplantation. We suggest that PPH may be linked to a specific variant of MIOP and recognizing the potential for pulmonary hypertension in children with MIOP may lead to a more rapid diagnosis and life-saving intervention.

show abstract

Pulmonary Hypertension

Cited by 46 publications

References 53 publications

Evaluation of Pimobendan and N‐Terminal Probrain Natriuretic Peptide in the Treatment of Pulmonary Hypertension Secondary to Degenerative Mitral Valve Disease in Dogs

Evaluation of Pimobendan and N‐Terminal Probrain Natriuretic Peptide in the Treatment of Pulmonary Hypertension Secondary to Degenerative Mitral Valve Disease in Dogs

Computed tomography and magnetic resonance imaging of pulmonary hypertension: Pulmonary vessels and right ventricle

Malignant infantile osteopetrosis & primary pulmonary hypertension: A new combination?

Contact Info

Product

Resources

About